Pancreatic Cancer Research

ResearcherCentral South UniversityActive in the last 2 years

Wenzhe Gao

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-2383-2371; OpenAlex author ID A5024294621. Sources: OpenAlex.

Their work

Papers
14 (first author 4, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
23
Papers, trials and grants by year

2020: 2 papers · 2021: 4 papers · 2022: 5 papers · 2023: none · 2024: 1 paper · 2025: 1 paper · 2026: 1 paper

Papers 14

  1. Prognostic Significance and Immune Landscape of Migrasome-Related Genes in Pancreatic Cancer. Co-author DOI 10.1007/s12010-026-05649-2↗
  2. Temporal trends in cross-country inequalities of early-onset pancreatic cancer: a comprehensive analysis for the global burden of disease study 2021. Co-author DOI 10.1038/s41598-025-93892-8↗
  3. IGF2BP2-related modification patterns in pancreatic cancer: A machine learning-driven approach towards personalized treatment. Co-author DOI 10.1016/j.heliyon.2024.e28243↗
  4. The NF-κB/miR-488/ERBB2 axis modulates pancreatic cancer cell malignancy and tumor growth through cell cycle signaling. Co-author DOI 10.1080/15384047.2022.2054257↗
  5. Identification of EMT-Related lncRNAs as Potential Prognostic Biomarkers and Therapeutic Targets for Pancreatic Adenocarcinoma. Co-author DOI 10.1155/2022/8259951↗
  6. Ferroptosis-Related IncRNAs Are Prognostic Biomarker of Overall Survival in Pancreatic Cancer Patients. First author DOI 10.3389/fcell.2022.819724↗
  7. Interplay of four types of RNA modification writers revealed distinct tumor microenvironment and biological characteristics in pancreatic cancer. Co-author DOI 10.3389/fimmu.2022.1031184↗
  8. DSCR9/miR-21-5p axis inhibits pancreatic cancer proliferation and resistance to gemcitabine via BTG2 signaling. Co-author DOI 10.3724/abbs.2022194↗
  9. S100A14 promotes progression and gemcitabine resistance in pancreatic cancer. First author DOI 10.1016/j.pan.2021.01.011↗
  10. Expressional and Prognostic Value of S100A16 in Pancreatic Cancer Via Integrated Bioinformatics Analyses. First author DOI 10.3389/fcell.2021.645641↗
  11. Development and Verification of the Hypoxia- and Immune-Associated Prognostic Signature for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fimmu.2021.728062↗
  12. Meta-analysis of the Diagnostic Performance of Circulating MicroRNAs for Pancreatic Cancer. Co-author DOI 10.7150/ijms.52706↗
  13. Multiomics integrative analysis for gene signatures and prognostic values of m6A regulators in pancreatic adenocarcinoma: a retrospective study in The Cancer G… Co-author DOI 10.18632/aging.103942↗
  14. Identification and Development of Long Non-coding RNA Associated Regulatory Network in Pancreatic Adenocarcinoma. First author DOI 10.2147/ott.s265036↗

Closest collaborators

The 23 strongest of 23 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Hongwei Zhu · 11 shared papers, 2020–2025 · strength 1.87
  2. Xiao Yu · 5 shared papers, 2021–2022 · strength 0.74
  3. Longjun Zang · 4 shared papers, 2021–2024 · strength 0.70
  4. Dongjie Chen · 4 shared papers, 2021–2024 · strength 0.70
  5. Xiao Yu · 3 shared papers, 2020–2024 · strength 0.47
  6. Ben Liu · 1 shared paper, 2026 · strength 0.33
  7. Sisi Li · 1 shared paper, 2026 · strength 0.33
  8. Yuting Xiao · 1 shared paper, 2026 · strength 0.33
  9. Yanyao Deng · 2 shared papers, 2020–2022 · strength 0.31
  10. Duo Han · 2 shared papers, 2022 · strength 0.31
  11. Yunfei Liu · 2 shared papers, 2021–2022 · strength 0.30
  12. Luohong Li · 1 shared paper, 2025 · strength 0.30
  13. Xiao Yu · 1 shared paper, 2022 · strength 0.17
  14. Shuai Wang · 1 shared paper, 2022 · strength 0.16
  15. Jixing Liu · 1 shared paper, 2022 · strength 0.16
  16. Hui Huang · 1 shared paper, 2021 · strength 0.16
  17. Xiao Yu · 1 shared paper, 2022 · strength 0.15
  18. Hui Huang · 1 shared paper, 2022 · strength 0.15
  19. Hongwei Zhu · 1 shared paper, 2020 · strength 0.15
  20. Wenjuan Zhu · 1 shared paper, 2020 · strength 0.15
  21. Guangping Tu · 1 shared paper, 2021 · strength 0.14
  22. Cheng Peng · 1 shared paper, 2021 · strength 0.14
  23. Wei Li · 1 shared paper, 2020 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.